Faculty Opinions recommendation of Comparison of three rating scales as outcome measures for treatment trials of depression in Alzheimer disease: findings from DIADS.

2007 ◽  
Author(s):  
Antonio Lobo
Keyword(s):  
Alzheimer Disease ◽  
Outcome Measures ◽  
Rating Scales ◽  
Treatment Trials

Comparison of three rating scales as outcome measures for treatment trials of depression in Alzheimer disease: findings from DIADS

2006 ◽  
Vol 21 (10) ◽  
pp. 930-936 ◽  
Author(s):  
Lawrence S. Mayer ◽  
R. Curt Bay ◽  
Antonios Politis ◽  
Martin Steinberg ◽  
Cynthia Steele ◽  
...  
Keyword(s):  
Alzheimer Disease ◽  
Outcome Measures ◽  
Rating Scales ◽  
Treatment Trials

Clinical Outcome Measures and Rating Scales in Multiple Sclerosis Trials

1997 ◽  
Vol 72 (11) ◽  
pp. 1070-1079 ◽  
Author(s):  
Dean M. Wingerchuk ◽  
John H. Noseworthy ◽  
Brian G. Weinshenker
Keyword(s):  
Multiple Sclerosis ◽  
Clinical Outcome ◽  
Outcome Measures ◽  
Rating Scales

P.5.4 Clinical outcome measures for dysferlinopathy: An exploration of reliability and suitability of novel functional rating scales

2013 ◽  
Vol 23 (9-10) ◽  
pp. 764-765
Author(s):  
M. Eagle ◽  
A.G. Mayhew ◽  
K. Bettinson ◽  
M.K. James ◽  
B. Von Rekowski ◽  
...  
Keyword(s):  
Clinical Outcome ◽  
Outcome Measures ◽  
Rating Scales

Rating scales as outcome measures for clinical trials in neurology: problems, solutions, and recommendations

2007 ◽  
Vol 6 (12) ◽  
pp. 1094-1105 ◽  
Author(s):  
Jeremy C Hobart ◽  
Stefan J Cano ◽  
John P Zajicek ◽  
Alan J Thompson
Keyword(s):  
Clinical Trials ◽  
Outcome Measures ◽  
Rating Scales

Key lessons learned from short-term treatment trials of cholinesterase inhibitors for amnestic MCI

2008 ◽  
Vol 20 (1) ◽  
pp. 40-46 ◽  
Author(s):  
Stephen Salloway ◽  
Stephen Correia ◽  
Sharon Richardson
Keyword(s):  
Cognitive Impairment ◽  
Outcome Measures ◽  
Primary Outcome ◽  
Rating Scales ◽  
Controlled Trial ◽  
Term Treatment ◽  
Lessons Learned ◽  
Secondary Outcome ◽  
Short Term ◽  
Short Term Treatment

ABSTRACTObjective: This paper reviews the key lessons learned from the first published short-term, placebo-controlled trial of a cholinesterase inhibitor for treatment of mild cognitive impairment (MCI).Methods: The study was a 24-week placebo-controlled trial designed to evaluate the efficacy and safety of donepezil HCl (donepezil) in the treatment of cognitive impairment in subjects with MCI. Primary outcome measures were the NYU Paragraphs Test and the ADCS Clinicians Global-Impression of Change in the intent-to-treat last-observation-carried-forward group.Results: There was no benefit of donepezil treatment on primary outcome measures (NYU Paragraphs and ADCS CGI-C) in the ITT-LOCF group but positive findings were seen on NYU Paragraphs in the fully evaluable group and in certain secondary outcome measures across both groups.Conclusions: The results highlight the need for the use of primary cognitive and functional measures that are reliable and sensitive to change in patients with MCI. Measures of episodic memory, psychomotor speed and complex attention were most sensitive in this study. Functional rating scales are needed that measure change in individual subjects' key areas of functional deficit, which typically involve executive aspects of instrumental ADLs. Tolerability can be increased by use of flexible dosing and efficacy is likely to be enhanced by increasing the length of the trial from six to 12 months and by enriching the sample with subjects more likely to decline during the trial.

Infantile gangliosidoses: candidate outcome measures for future treatment trials

2017 ◽  
Vol 120 (1-2) ◽  
pp. S133
Author(s):  
Jeanine Utz ◽  
Sarah Kim ◽  
Kelly King ◽  
Richard Ziegler ◽  
Lynn Schema ◽  
...  
Keyword(s):  
Outcome Measures ◽  
Treatment Trials ◽  
Future Treatment
Sign in / Sign up

Export Citation Format

Share Document